Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

Netakimab (NTK) is a humanized anti-interleukin-17A monoclonal antibody. To date, the drug has been approved to treat ankylosing spondylitis (AS), psoriatic arthritis, and plaque psoriasis. The paper gives the data obtained during 52-week follow-up of AS patients in the phase III ASTERA study.Object...

Full description

Bibliographic Details
Main Authors: V. I. Mazurov, Sh. F. Erdes, I. Z. Gaydukova, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, E. P. Ilivanova, A. V. Strelkova, A. V. Eremeeva, A. V. Zinkina-Orikhan
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2020-11-01
Series:Современная ревматология
Subjects:
netakimab
ankylosing spondylitis
radiographic axial spondyloarthritis
interleukin-17 inhibitors
Online Access:https://mrj.ima-press.net/mrj/article/view/1067

Internet

https://mrj.ima-press.net/mrj/article/view/1067

Similar Items